MedTrace Logo

Combined Anticancer Treatment of Advanced Colon Cancer

NCT01540344 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2018-09-05

No results posted yet for this study

Summary

The COMBATAC study evaluates the the effect as assessed by progression-free survival (PFS) of perioperative systemic chemotherapy including cetuximab and cytoreductive surgery (CRS) and bidirectional hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal carcinomatosis arising from colorectal cancer.

Conditions

  • Peritoneal Carcinomatosis
  • Colorectal Cancer Metastatic

Interventions

PROCEDURE

CRS

complete macroscopic cytoreduction (CC-0/1)

DRUG

HIPEC

bidirectional hyperthermic intraperitoneal chemotherapy (HIPEC) with 400 mg/sqm 5-FU + 20 mg/sqm folinic acid IV and 300 mg/sqm oxaliplatin IP

Sponsors & Collaborators

  • Heinrich-Heine University, Duesseldorf

    collaborator OTHER

  • University of Regensburg

    lead OTHER

Principal Investigators

  • Pompiliu Piso, Prof. MD · University of Regensburg

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
71 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2015-09-30
Completion
2017-10-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01540344 on ClinicalTrials.gov